Supplementary Table S1. Correlation between MALAT1 expression in PBMC (unstimulated and IFN-α-stimulated PBMC) from patients with primary Sjögren's syndrome and serologic features.

Serologic features	Unstimulated PBMCs		IFN-α-stimulated PBMCs	
	Correlation coefficient (IC 95%)	p	Correlation coefficient (IC 95%)	p
C4	-0.308 (-0.757 to 0.340)	0.327	-0.189 (-0.698 to 0.447)	0.553
C3	-0.384 (-0.792 to 0.261)	0.218	-0.489 (-0.836 to 0.136)	0.109
Leukocytes	-0.143 (-0.653 to 0.457)	0.638	-0.253 (-0.741 to 0.362)	0.400
Hemoglobin	0.104 (-0.487 to 0.631)	0.732	0.162 (-0.441 to 0.665)	0.593
Creatinine	-0.244 (-0.710 to 0.369)	0.417	0.310 (-0.306 to 0.744)	0.299
CRP	-0.181 (-0.675 to 0.425)	0.553	-0.027 (-0.582 to 0.544)	0.935
ESR	-0.278 (-0.727 to 0.338)	0.354	-0.159 (-0.663 to 0.443)	0.599
Platelets	-0.291 (-0.734 to 0.325)	0.334	-0.269 (-0.723 to 0.347)	0.374

C4: complement 4; CRP: C-reactive protein, ESR: erythrocyte sedimentation rate; IC: confidence interval.
Spearman correlation test was used to assess the association between MALAT1 expression in unstimulated PBMC and IFN-α-stimulated PBMC from pSS patients with different variables.

Supplementary Table S2. Correlation between MALAT1 expression in PBMCs (unstimulated and IFN-α stimulated PBMCs) from patients with primary Sjögren's syndrome and ISGs expression.

ISGs	Unstimulated PBMCs		IFN-α-stimulated PBMCs	
	Correlation coefficient (IC 95%)	p	Correlation coefficient (IC 95%)	p
ISG15	0.271 (-0.345 to 0.724)	0.368	-0.260 (-0.718 to 0.355)	0.388
LY6E	-0.063 (-0.605 to 0.518)	0.838	-0.076 (-0.613 to 0.508)	0.806
OAS1	0.388 (-0.224 to 0.781)	0.189	0.076 (-0.508 to 0.613)	0.806
MX1	0.288 (-0.328 to 0.733)	0.335	0.181 (-0.425 to 0.675)	0.553
OASL	0.016 (-0.552 to 0.574)	0.959	-0.186 (-0.678 to 0.421)	0.541

ISG15: Interferon-stimulated gene 15; LY6E: lymphocyte antigen 6 complex locus E; OAS1: 2'5'-oligoadenylate synthetase 1; MX1: myxovirus resistance 1; OASL: oligoadenylate synthase-like; IC: confidence interval.
Spearman correlation test was used to assess the association between MALAT1 expression in PBMCs from pSS patients and ISGs expression.

Supplementary Table S3. Correlation between MALAT1 expression in PBMCs (unstimulated and IFN-α stimulated PBMCs) from patients with primary Sjögren's syndrome and secretion levels of interferon-regulated chemokines.

ISGs	Unstimulated PBMCs		IFN-α-stimulated PBMCs	
	Correlation coefficient (IC 95%)	p	Correlation coefficient (IC 95%)	p
MCP-1	0.159 (-0.444 to 0.663)	0.604	0.148 (-0.453 to 0.657)	0.629
MIP-1α	0.054 (-0.524 to 0.600)	0.863	-0.186 (-0.678 to 0.421)	0.541
IP-10	0.462 (-0.137 to 0.813)	0.113	0.170 (-0.435 to 0.669)	0.578
BLC	-0.014 (-0.573 to 0.554)	0.966	-0.035 (-0.587 to 0.538)	0.910

MCP-1: monocyte chemoattractant protein-1; MIP-1α: macrophage inflammatory protein-1 alpha; IP10: interferon γ-induced protein 10; BLC: B lymphocyte chemoattractant; IC: confidence interval.
Spearman correlation test was used to assess the association between MALAT1 expression in PBMCs from pSS patients and secretion levels of Interferon-regulated chemokines.